SOLICITATION NOTICE
B -- Functional characterization of mutations manual using patch clamp techniques
- Notice Date
- 6/21/2016
- Notice Type
- Presolicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- HHS-NIH-NHLBI-CSB-(HG)-2016-189-DM
- Archive Date
- 7/12/2016
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352
- E-Mail Address
-
maxwelld@mail.nih.gov
(maxwelld@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- INTRODUCTION: THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR A PROPOSAL. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The National Institute of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) Office of Acquisition (OA) on behalf of the National Human Genome Research Institute (NHGRI) Undiagnosed Disease Program, intends to negotiate and award a purchase order on a noncompetitive sole source basis without providing for full and open competition to B'SYS GmbH, Benkenstrasse 254, Witterswil, SO, 4108, Switzerland to procure the following: Procurement: 1. Functional characterization of mutations manual using patch clamp techniques. Comparison of results with unmutated/ wild form properties for NIH/NHGRI Undiagnosed Disease Program. Background: The National Institute of Health (NIH) is the nation's leading medical research agency and the primary Federal agency conducting, supporting and making medical discoveries that improve people's health and save lives. The National Institutes of Health Undiagnosed Disease Program (UDP) is a trans-National Institute of Health (NIH) initiative organized by the NHGRI, the NIH Office of Rare Diseases Research (ORDR) and the NIH Clinical center that focuses on the most puzzling medical cases referred to the NIH Clinical Center with a mission that has expanded to encompass a broad range of studies aimed at understanding the structure and function of the human genome and its role in health and diseases. The goals of the UDP include finding accurate diagnoses and discovering new diseases that provide insight into human physiology and genetics. The UDP was established to evaluate participants who have undiagnosed medical conditions. UDP participants have generally received extensive diagnostic workups before traveling to the NIH and often have numerous and/or complex medical problems. In order to determine the function of genes that are mutated in UDP patients and how these interact with ion channels or receptors that lead to seizures in these individuals, the Contractor will perform patch clamp analysis using extracts from NIH provided mutation constructs. This work will provide a screening mechanism and continue to support the UDP by providing functional analysis of suspected gene mutations to determine how they generate seizure activity in UDP patients. Purpose and Objective: The purpose of this acquisition is to provide functional characterization of four mutated genes seen in NIH Undiagnosed Diseases Program patients. Specifically, this acquisition supports the research needs of the UDP by providing functional analysis of ion channels or receptors that will further elucidate the mechanism that causes UDP patient disease phenotypes. In order to determine the function of genes that are mutated in UDP patients and how these interact with ion channels or receptors that lead to seizures in these individuals, the Contractor will perform patch clamp analysis using extracts from NIH provided mutation constructs. This work will provide a screening mechanism and continue to support the UDP by providing functional analysis of suspected gene mutations to determine how they generate seizure activity in UDP patients. The NIH UDP program admits patients with rare and undiagnosed diseases. Through next-generation sequencing, genes that may be related to the disease phenotype are identified, including those that may be involved in epilepsy or seizures. In a subset of patients, however, the genes that are identified have unknown function. It is the purpose of this study is to use a more cost-effective screening method to explore the functions of these genes in relation to their ability to modulate ion channels or receptors, and their ultimate involvement in seizures. In order to gain this knowledge, the Contractor will provide functional characterizations of these gene mutations using patch clamp techniques and compare the results with wild-type gene function. Other Important Considertion: Contractor's Requirements: • The contractor shall compare pairs of wild-type and mutated ion channels to determine functional properties. • The contractor will provide a target vector to the NIH along with information regarding the vector/map and restriction sites in order for the NIH UDP to clone the gene into the target vector and return to the Contractor for performing the study. • The contractor shall perform appropriate ion channel studies pertaining to the specific type designated by the NIH UDP prior to evaluation. • The contractor shall perform cell culture and transient transfection of the constructs into standard expression systems. • The contractor shall select transfected cells by light microscopy and perform patch clamping in the whole cell state. • The contractor shall provide the biophysical analysis results as well as pharmacological validation information. o Determine ion selectivity/conductance at n=3 o Establish activation/inactivation curves o Determine channel types at n=3 o Determine basic response to a general and/or specific blocker at individual concentrations and at n=3 • The contractor shall report data within two months after receipt of NIH UDP cDNA construct. Period of Performance: 12-Months Additional Information: Industry Classification (NAICS) Code is 541712, Research and Development in the Physical, Engineering, and Life Sciences (except biotechnology) and small business size standard is 500. The acquisition is being conducted under FAR Part 13, simplified acquisition procedures, therefore the requirements of FAR Part 6 B Competitive Requirements are not applicable (FAR Part 6.001). The resultant Contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-88-1 (June 15, 2016). This requirement is under the Simplified Acquisition Threshold of $150,000.00. This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received June 27, 2016 and must reference synopsis number HHS-NIH-NHLBI-CSB-(HG)-2016-189-DM, may be submitted to the National, Heart, Lung and Blood Institute, Office of Acquisition, COAC Services Branch, 6701 Rockledge Drive, Suite 6149, Bethesda, Maryland 20892-7902, Attention: Dorothy Maxwell. Response may be submitted electronically to maxwelld@mail.nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative. "All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency."
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/HHS-NIH-NHLBI-CSB-(HG)-2016-189-DM/listing.html)
- Place of Performance
- Address: NIH and Contractor's Location, United States
- Record
- SN04156304-W 20160623/160621234125-bcc187ee4c03cde47aae0810b398d27f (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |